This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tincani, A Articles by Doria, A Search for Related Content PubMed PubMed Citation Articles by Tincani, A Articles by Doria, A Social Bookmarking                   What's this?

Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome)

Rheumatology and Clinical Immunology, Brescia Hospital and University, Italy, tincani{at}bresciaseumatologia.it

D Bompane

Rheumatology Department, University of Rome, "La Sapienza", Italy

E Danieli

Rheumatology and Clinical Immunology, Brescia Hospital and University, Italy

A Doria

Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Italy

Autoimmune diseases (AD) occur frequently in women during their childbearing years and may influence pregnancy outcome and neonatal health. Patients with systemic lupus erythematosus (SLE) can experience a disease flare-up during pregnancy with potential negative effects on the product of conceptus, especially if the disease is active. Recurrent pregnancy loss is now considered as a treatable clinical condition associated with the presence of circulating antiphospholipid antibodies (aPL). The neonatal lupus syndromes (NLS), caused by the transplacental passage of maternal IgG anti-Ro/SS-A and anti-La/SS-B antibodies to the fetus, carry significant morbidity and mortality in case of cardiac manifestations. Immunosuppressive agents are often administered during pregnancy in order to control maternal disease and to ensure a better pregnancy outcome. Nowadays, owing to our increasing knowledge of the disease pathophysiological mechanisms and the development of combined medical-obstetric clinics, pregnancy outcome in patients with AD has notably improved.

Key Words: antiphospholipid syndrome • immunosuppressive drugs • neonatal lupus syndrome • pregnancy • systemic lupus erythematosus

Lupus, Vol. 15, No. 3, 156-160 (2006)
DOI: 10.1191/0961203306lu2279rr


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Mecacci, B. Bianchi, A. Pieralli, B. Mangani, A. Moretti, R. Cioni, L. Giorgi, G. Mello, and M. Matucci-Cerinic Pregnancy outcome in systemic lupus erythematosus complicated by anti-phospholipid antibodies Rheumatology, March 1, 2009; 48(3): 246 - 249. [Abstract] [Full Text] [PDF]

				A. Doria, A. Tincani, and M. Lockshin Challenges of lupus pregnancies Rheumatology, June 1, 2008; 47(suppl_3): iii9 - iii12. [Abstract] [Full Text] [PDF]

				J. F. Smith Jr and M. L. Druzin Perinatal Implications of the Antiphospholipid Syndrome NeoReviews, May 1, 2007; 8(5): e206 - e213. [Abstract] [Full Text] [PDF]